<DOC>
	<DOCNO>NCT00081627</DOCNO>
	<brief_summary>The objective trial determine CoFactor combination 5-FU effective treatment metastatic colorectal cancer determine side effect observe administration CoFactor 5-FU .</brief_summary>
	<brief_title>Clinical Trial Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Patients must surgically incurable colon rectal adenocarcinoma Karnofsky Performance Status 60 % great Patients may symptomatic neuropathy Patients must life expectancy least 4 month Patients must aliment , receive least 1500Kcal/day nutrition , route Patients must bidimensional measurable disease response assessment Patients may receive adjuvant chemotherapy fluoropyrimidine therapy Patients must recover toxicity prior therapy , least 4 week since prior adjuvant chemotherapy major surgery Serum creatinine le 2.4mg % , serum bilirubin le 3.0mg % , WBC great 3,200/mm2 , AGC great 1,500/mm3 , platelet count great 90,000/mm3 SGOT ( AST ) SGPT ( ALT ) less 3 time upper limit normal Male nonpregnant , nonlactating female patient must &gt; 18 year old . Concurrent infection Failure patient patient 's legal representative sign Informed consent Inability obtain Informed Consent psychiatric complex medical problem Patients unstable oncologic emergency Patients unstable medical condition angina , transient ischemic attack , rise creatinine , accelerate hypertension , etc . Cerebellar neurologic syndrome Parkinson 's Disease , multiple sclerosis amyotonia Known intolerance fluoropyrimidine therapy suggestive dihydropyrimidine dehydrogenase deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>